Vivace Therapeutics has discovered, and is now developing, multiple novel small-molecule medicines targeting the Hippo-YAP pathway, which has shown to be involved in the regulation of cell proliferation, programmed cell death and cell migration.
In healthy conditions, this pathway controls tissue regeneration and the size and shape of organs. However, mutations of the YAP pathway can contribute to a wide range cancers including gastric, colon, cervical, ovarian, breast, uveal melanoma, mesothelioma, hepatocellular carcinoma and esophageal squamous cell carcinoma. YAP activity is also linked to resistance to targeted therapies and to cancer relapse.
With an industry-leading understanding of the YAP pathway’s complex biology, Vivace is bringing forth a new generation of cancer therapeutics in the form of YAP-TEAD transcription activity inhibitors.
Recently, the Hippo-YAP Pathway kinases LATS1/2 were found to play a role in suppressing anti-tumor immunity in the UCSD laboratory of our scientific founder Dr. Kun-liang Guan. LATS1/2 deletion in tumors enhances tumor immunogenicity, leading to tumor growth inhibition. Vivace Therapeutics is discovering and developing innovative medicines in cancer immunotherapy by targeting LATS1/2.